Therapeutic anticoagulation after liver transplantation is not useful among patients with pre‐transplant Yerdel‐grade I/II portal vein thrombosis: A two‐center retrospective study
| Autor: | Isabel Bos, Marc Blondeau, Michel Rayar, Dune Wouters, Willemijn van der Plas, Christophe Camus, Vincent E de Meijer, Pauline Houssel-Debry, Robert J. Porte, Lianne M Nieuwenhuis, Edouard Bardou-Jacquet, Ton Lisman |
|---|---|
| Přispěvatelé: | Groningen Institute for Organ Transplantation (GIOT), Center for Liver, Digestive and Metabolic Diseases (CLDM) |
| Rok vydání: | 2021 |
| Předmět: |
Adult
Liver Cirrhosis medicine.medical_specialty recurrence Cirrhosis genetic structures medicine.medical_treatment therapeutic anticoagulation Liver transplantation EVENTS mental disorders medicine Humans portal vein thrombosis Risk factor CIRRHOSIS Contraindication Retrospective Studies Venous Thrombosis Portal Vein business.industry Incidence (epidemiology) Anticoagulants Retrospective cohort study Hematology Odds ratio medicine.disease Liver Transplantation Surgery Portal vein thrombosis Treatment Outcome Yerdel INVERSE PROBABILITY business |
| Zdroj: | Journal of Thrombosis and Haemostasis, 19(11), 2760-2771. Wiley |
| ISSN: | 1538-7836 1538-7933 |
| Popis: | BACKGROUND: Portal vein thrombosis (PVT) is no longer a contraindication for liver transplantation (LT). While therapeutic anticoagulation (tAC) is recommended during the waiting period, there is no evidence for its usefulness in the prevention of PVT recurrence after LT.OBJECTIVES: The aim of our study was to evaluate the role of tAC post-LT in the prevention of PVT recurrence.PATIENTS/METHODS: All adult LTs performed in 2 high volume centres between 2003 and 2018, were retrospectively analysed. Only patients with PVT classified as Yerdel grade I or II and with standard portal reconstruction were included. PVT recurrence and tAC-associated morbidity within 1 year were compared between patients receiving tAC or not.RESULTS: During the study period, out of 2612 LTs performed, 235 (9%) patients with PVT were included. 113 patients (48.1%) received post-LT tAC (tAC group) while 122 (51.9%) did not (non-tAC group). The incidence of bleeding events was significantly higher in the tAC group (26 (23%) vs. 5 (4.1%), pCONCLUSION: Therapeutic anticoagulation is not necessary in the prevention of grade I/II PVT recurrence and is associated with higher morbidity and longer hospital stay. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text